Addition of FFRct in the diagnostic pathway of patients with stable chest pain to reduce unnecessary invasive coronary angiography (FUSION) : Rationale and design for the multicentre, randomised, controlled FUSION trial.

"Conflict of interest S.P. Sharma, A. Hirsch, M.G.M. Hunink, M.J.M. Cramer, F.A.A. Mohamed Hoesein, C.A. Geluk, G. Kramer, J.W.C. Gratama, R.L. Braam, P.M. van der Zee, W. Yassi, S.L. Wolters, C. Gürlek, G. Pundziute, R. Vliegenthart and R.P.J. Budde declare that they have no competing interests. This study is financially supported by HeartFlow, Inc. In addition, the Erasmus Medical Centre has received support from HeartFlow, Inc. and Siemens for other studies unrelated to the FUSION trial."

"Funding This work was supported by the Dutch Ministry of Health and the Dutch National Health Care Institute (Zorginstituut Nederland) as part of the research programme ‘Potentially Promising Care’ (‘Veelbelovende Zorg’) and HeartFlow, Inc."

"The study complies with good clinical practice in accordance with the Declaration of Helsinki and the laws and regulations applicable in the Netherlands, including the General Data Protection Regulation, as the clinical trial has been approved by the appropriate Medical Research Ethics Committee and Review Board (Erasmus MC, MEC-2021-0189). The clinical trial was registered under number NL76830.078.21 (NCT05174247, clinical trial registration number) on 29 December 2021. The trial started enrolment on 28 July 2021."